Use of Rituximab in the treatment of extensive chronic graft versus host disease after allogenic stem cells transplantation.

Next Previous
Trial Profile

Use of Rituximab in the treatment of extensive chronic graft versus host disease after allogenic stem cells transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2011

At a glance

  • Drugs Rituximab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top